Teraparin is a recombinant form of parathyroid hormone consisting of a first (N-terminal) 34 amminoacido, which is a biologically active part of the hormone. It is an effective anabolic (ie, bone) agent for the treatment of certain forms of osteoporosis. And sometimes use de-labeling to accelerate fracture healing. Trepipril is identical to a part of human parathyroid hormone (PTH), which is used intermittently to activate osteoblasts than osteoclasts, resulting in an overall increase in bones.
Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
Purezza (HPLC): 95.0%min.
Aspetto esteriore: polvere bianca
Singola impurità (HPLC): 2.0%max
Composizione di amminoacidi: ±10% del teorico
Contenuto peptidico (N%): ≥80,0%
Contenuto di acqua (Karl Fischer): ≤10,0%
Contenuto in acetato (HPC): ≤15,0%
SM (ESI): Coerente
Bilancio di massa: 95.0~105,0%
